Radiation Therapy With or Without Apalutamide in Treating Patients With Stage III-IV Prostate Cancer
Status: | Recruiting |
---|---|
Conditions: | Prostate Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 2/13/2019 |
Start Date: | April 27, 2018 |
End Date: | October 31, 2028 |
Contact: | Daniel Spratt, MD |
Email: | sprattda@med.umich.edu |
Phone: | 734-232-5244 |
A Phase II, Double-Blinded, Placebo Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-androgen Therapy With Apalutamide in Recurrent Prostate Cancer
This phase II trial studies how well radiation therapy with or without apalutamide works in
treating patients with stage III-IV prostate cancer. Radiation therapy uses high energy x-ray
to kill tumor cells and shrink tumors. Androgen can cause the growth of prostate cancer
cells. Drugs, such as apalutamide, may lessen the amount of androgen made by the body. Giving
radiation therapy and apalutamide may work better at treating prostate cancer than radiation
alone.
treating patients with stage III-IV prostate cancer. Radiation therapy uses high energy x-ray
to kill tumor cells and shrink tumors. Androgen can cause the growth of prostate cancer
cells. Drugs, such as apalutamide, may lessen the amount of androgen made by the body. Giving
radiation therapy and apalutamide may work better at treating prostate cancer than radiation
alone.
PRIMARY OBJECTIVES:
I. To determine whether, in men with post-prostatectomy PSA recurrences, salvage radiation
(SRT) with enhanced anti-androgen therapy with apalutamide will improve biochemical
progression-free survival (bPFS) compared to SRT alone.
SECONDARY OBJECTIVES:
I. To assess whether molecular stratification by the PAM50 gene expression clustering will
identify subsets of prostate cancer (luminal A or basal, luminal B) which derive the greatest
benefit from anti-androgen therapy.
II. To assess overall survival. III. To assess cancer-specific mortality. IV. To assess
metastasis-free survival. V. To assess distant metastasis. VI. To assess local-regional
progression. VII. To assess PSA nadir during first year of treatment and prior to initiation
of any hormonal salvage therapy.
VIII. To assess initiation of salvage hormonal therapy. IX. To assess PSA with a non-castrate
testosterone at 1 and 3 years post randomization: PSA < 0.1 ng/ml and testosterone >= 50
ng/dl.
X. To assess acute and late physician-reported morbidity (per the Common Terminology Criteria
for Adverse Events [CTCAE] version 5) after SRT +/- apalutamide.
XI. To assess acute and late patient-reported morbidity (per the patient reported outcomes
[PRO]-CTCAE) after SRT +/- apalutamide.
XII. To assess testosterone levels at 3, 6, 9, 12, and 36 months post randomization.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM 1: Patients undergo external beam radiation therapy on Day 1 for 7.5 weeks. Beginning on
Day 1 of radiation therapy, patients receive placebo orally (PO) once daily (QD) on days
1-30. Treatment repeats every 30 days for up to 6 courses (6 months) in the absence of
disease progression or unacceptable toxicity.
ARM 2: Patients undergo external beam radiation therapy on Day 1 for 7.5 weeks. Beginning on
Day 1 of radiation therapy, patients receive apalutamide PO QD on Days 1-30. Treatment
repeats every 30 days for up to 6 courses (6 months) in the absence of disease progression or
unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years,
then every 6 months for 3 years, and then yearly thereafter.
I. To determine whether, in men with post-prostatectomy PSA recurrences, salvage radiation
(SRT) with enhanced anti-androgen therapy with apalutamide will improve biochemical
progression-free survival (bPFS) compared to SRT alone.
SECONDARY OBJECTIVES:
I. To assess whether molecular stratification by the PAM50 gene expression clustering will
identify subsets of prostate cancer (luminal A or basal, luminal B) which derive the greatest
benefit from anti-androgen therapy.
II. To assess overall survival. III. To assess cancer-specific mortality. IV. To assess
metastasis-free survival. V. To assess distant metastasis. VI. To assess local-regional
progression. VII. To assess PSA nadir during first year of treatment and prior to initiation
of any hormonal salvage therapy.
VIII. To assess initiation of salvage hormonal therapy. IX. To assess PSA with a non-castrate
testosterone at 1 and 3 years post randomization: PSA < 0.1 ng/ml and testosterone >= 50
ng/dl.
X. To assess acute and late physician-reported morbidity (per the Common Terminology Criteria
for Adverse Events [CTCAE] version 5) after SRT +/- apalutamide.
XI. To assess acute and late patient-reported morbidity (per the patient reported outcomes
[PRO]-CTCAE) after SRT +/- apalutamide.
XII. To assess testosterone levels at 3, 6, 9, 12, and 36 months post randomization.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM 1: Patients undergo external beam radiation therapy on Day 1 for 7.5 weeks. Beginning on
Day 1 of radiation therapy, patients receive placebo orally (PO) once daily (QD) on days
1-30. Treatment repeats every 30 days for up to 6 courses (6 months) in the absence of
disease progression or unacceptable toxicity.
ARM 2: Patients undergo external beam radiation therapy on Day 1 for 7.5 weeks. Beginning on
Day 1 of radiation therapy, patients receive apalutamide PO QD on Days 1-30. Treatment
repeats every 30 days for up to 6 courses (6 months) in the absence of disease progression or
unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years,
then every 6 months for 3 years, and then yearly thereafter.
Inclusion Criteria:
- Pathologically (histologically) proven diagnosis of prostate adenocarcinoma;
prostatectomy must have been performed within 10 years prior to Step 1 registration
and any type of radical prostatectomy is permitted, including retropubic, perineal,
laparoscopic or robotically assisted
- Post-prostatectomy patients with a detectable serum PSA (≥ 0.1, but ≤ 1.0 ng/mL) at
study entry (within 90 days of Step 1 registration) and at least one of the following:
- Gleason score 7-10 (International Society of Urological Pathology [ISUP] grade
group 2 to 5)
- ISUP grade group:
- Grade Group 1: Gleason score ≤ 6,
- Grade Group 2: Gleason score 3 + 4 = 7,
- Grade Group 3: Gleason score 4 + 3 = 7,
- Grade Group 4: Gleason score 8,
- Grade Group 5: Gleason scores 9 and 10
- >= T3a disease
- Persistent elevation of PSA after prostatectomy measured within 90 days after
surgery (PSA never became undetectable) of > 0.04 but < 0.2 ng/mL (PSA nadir)
- pN0 or pNx
- History/physical examination within 90 days prior to Step 1 registration
- Karnofsky performance status of 70-100 within 90 days prior to Step 1 registration
- Surgical formalin-fixed paraffin-embedded (FFPE) specimen must be available for
submission to GenomeDx for genomic analysis on Decipher GRID platform; Note: if
Decipher results have already been obtained, in lieu of tissue, results must be
submitted to GenomeDx for validation
- Prior androgen deprivation therapy (luteinizing hormone-releasing hormone [LHRH]
agonist and/or non-steroidal anti-androgen) is allowed if discontinued at least 90
days prior to Step 1 registration and given for ≤ 90 days duration
- For example: patients on prior LHRH analogs (post-prostatectomy), the
discontinuation date should be calculated based on the expected duration of the
sustained release injection, not simply the injection date of the drug; for
instance, if a 22.5 mg sustained release dose of leuprolide acetate is given (3
month duration), then the expected duration of such a dose would be 90 days after
the injection date; for a 7.5 mg leuprolide (1 month duration), the
discontinuation date would be 30 days after the injection date
- Please note: finasteride or dutasteride must be stopped before treatment starts
but prior usage will not affect eligibility
- Hemoglobin ≥ 9.0 g/dL, independent of transfusion and/or growth factors within 90 days
prior to Step 1 registration
- Platelet count ≥ 100,000 x 10^9/uL independent of transfusion and/or growth factors
within 90 days prior to step 1 registration
- Serum albumin ≥ 3.0 g/dL within 90 days prior to Step 1 registration
- Glomerular filtration rate (GFR) ≥ 35 mL/min estimated by Cockcroft-Gault or measured
directly by 24 hour urine creatinine within 90 days prior to Step 1 registration
- Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) (Note: in subjects with
Gilbert's syndrome, if total bilirubin is > 1.5 x ULN, measure direct and indirect
bilirubin and if direct bilirubin is ≤ 1.5 x ULN, subject is eligible) within 90 days
prior to Step 1 registration
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 x ULN within
90 days prior to Step 1 registration
- Testosterone > 50 ng/dL within 90 days prior to Step 1 registration
- Concomitant medications known to lower the seizure threshold discontinued or
substituted at least 4 weeks (30 days) prior to Step 1 registration.
- The patient must agree to use a condom (even men with vasectomies) and another
effective method of birth control if he is having sex with a woman of childbearing
potential or agree to use a condom if he is having sex with a woman who is pregnant
while on study drug and for 3 months following the last dose of study drug
- The patient must agree not to donate sperm during the study treatment and for 3 months
after receiving the last dose of study drug
- The patient or a legally authorized representative must provide study-specific
informed consent prior to study entry
Exclusion Criteria:
- Definitive clinical, radiologic, or pathologic evidence of metastatic disease (M1) or
lymph node involvement (N1)
- Prior invasive malignancy (except non-melanomatous skin cancer, carcinoma in situ of
the male breast, penis, oral cavity, or stage Ta of the bladder, or stage I completely
resected melanoma) unless disease free for a minimum of 2 years
- Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a
different cancer is allowable
- Prior radiotherapy to the region of the study cancer that would result in overlap of
radiation therapy fields
- History of any of the following:
- Seizure or known condition that may pre-dispose to seizure (e.g. prior stroke
within 1 year prior to Step 1 registration)
- History of documented inflammatory bowel disease
- Transmural myocardial infarction within the last 4 months prior to Step 1
registration.
- Unstable angina and/or congestive heart failure requiring hospitalization within
the last 6 months prior to Step 1 registration
- History of any condition that in the opinion of the investigator, would preclude
participation in this study
- Current evidence of any of the following:
- Known gastrointestinal disorder affecting absorption of oral medications
- Active uncontrolled infection (eg, human immunodeficiency virus [HIV] or viral
hepatitis)
- Uncontrolled hypertension
- Any current condition that in the opinion of the investigator, would preclude
participation in this study
- Prior whole gland ablative therapy (i.e. cryoablation or high intensity focused
ultrasound [HIFU]) for prostate cancer is not allowed
- HIV positive with CD4 count < 200 cells/microliter within 30 days prior to
registration
- HIV patients under treatment with highly active antiretroviral therapy (HAART) within
30 days prior to registration regardless of CD4 count. (Note: HIV testing is not
required for eligibility for this protocol as it is self-reported.)
- For patients who have not undergone prior Decipher analysis, submission of the
specimen to GenomeDx should be as soon as possible after study registration (Step 1)
as these results can take up 21 days after the specimen is received at GenomeDx; Step
2 registration must occur within 6 weeks (42 days) of Step 1 registration; if Decipher
results have already been obtained, in lieu of tissue, results must be submitted to
GenomeDx for validation
We found this trial at
216
sites
Toronto, Ontario
Principal Investigator: Alejandro Berlin
Phone: 416-946-4501
Click here to add this to my saved trials
1 South Prospect Street
Burlington, Vermont 05401
Burlington, Vermont 05401
802-656-8990
Principal Investigator: Harold J. Wallace
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
Click here to add this to my saved trials
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
Las Vegas, Nevada 89102
(702) 383-2000
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
Click here to add this to my saved trials
529 West Markham Street
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
(501) 686-7000
Principal Investigator: Sanjay Maraboyina
Phone: 501-686-8274
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
Click here to add this to my saved trials
4502 Medical Drive
San Antonio, Texas 78284
San Antonio, Texas 78284
(210) 567-7000
Principal Investigator: Chethan Ramamurthy
Phone: 210-450-3800
University of Texas Health Science Center at San Antonio The University of Texas Health Science...
Click here to add this to my saved trials
Akron, Ohio 44304
Principal Investigator: Desiree E. Doncals
Phone: 330-375-6101
Click here to add this to my saved trials
170 North 1100 East
American Fork, Utah 84003
American Fork, Utah 84003
Principal Investigator: Brandon M. Barney
Phone: 801-855-4100
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Daniel E. Spratt
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Samir Narayan
Phone: 734-712-3671
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
Click here to add this to my saved trials
Atlanta, Georgia 30303
Principal Investigator: Ashesh B. Jani
Phone: 404-489-9164
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Ashesh B. Jani
Phone: 404-778-1868
Click here to add this to my saved trials
550 Peachtree St NE
Atlanta, Georgia 30308
Atlanta, Georgia 30308
(404) 686-4411
Principal Investigator: Ashesh B. Jani
Phone: 888-946-7447
Emory University Hospital Midtown Emory University Hospital Midtown is a 511-bed community-based, acute care teaching...
Click here to add this to my saved trials
Atlanta, Georgia 30342
Principal Investigator: Ashesh B. Jani
Phone: 412-339-5294
Click here to add this to my saved trials
Baltimore, Maryland 21229
Principal Investigator: Richard S. Hudes
Phone: 410-368-2910
Click here to add this to my saved trials
265 Fremont St
Battle Creek, Michigan 49017
Battle Creek, Michigan 49017
(269) 245-8166
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
Click here to add this to my saved trials
3535 Pentagon Boulevard
Beavercreek, Ohio 45431
Beavercreek, Ohio 45431
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
Bellingham, Washington 98225
Principal Investigator: Benjamin B. Bridges
Phone: 360-715-4133
Click here to add this to my saved trials
Bennington, Vermont 05201
Principal Investigator: Alan C. Hartford
Phone: 802-447-1836
Click here to add this to my saved trials
Berkeley, California 94704
Principal Investigator: Christopher U. Jones
Phone: 415-209-2686
Click here to add this to my saved trials
Berlin, Vermont 05602
Principal Investigator: Harold J. Wallace
Phone: 802-225-5400
Click here to add this to my saved trials
Bethlehem, Pennsylvania 18015
Principal Investigator: Nimisha Deb
Phone: 412-339-5294
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Brighton, Michigan 48114
Principal Investigator: Samir Narayan
Phone: 734-712-3671
Click here to add this to my saved trials
Burlington, Vermont 05405
Principal Investigator: Harold J. Wallace
Phone: 802-656-4101
Click here to add this to my saved trials
201 E Nicollet Blvd
Burnsville, Minnesota 55337
Burnsville, Minnesota 55337
(952) 892-2000
Principal Investigator: Paul W. Sperduto
Phone: 952-993-1517
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Canton, Michigan 48188
Principal Investigator: Samir Narayan
Phone: 734-712-3671
Click here to add this to my saved trials
789 Mt Auburn Rd
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
(573) 519-4725
Principal Investigator: Bryan A. Faller
Phone: 573-651-5550
Southeast Cancer Center SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital...
Click here to add this to my saved trials
1303 North Main Street
Cedar City, Utah 84721
Cedar City, Utah 84721
(435) 868-5680
Principal Investigator: Brandon M. Barney
Phone: 435-868-5680
Sandra L. Maxwell Cancer Center The Huntsman-Intermountain Cancer Center at Valley View Medical Center in...
Click here to add this to my saved trials
Centerville, Ohio 45459
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
Centerville, Ohio 45459
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
Chadds Ford, Pennsylvania 19317
Principal Investigator: Gregory A. Masters
Phone: 302-623-4450
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
Principal Investigator: Ronald C. Chen
Phone: 877-668-0683
Click here to add this to my saved trials
775 South Main Street
Chelsea, Michigan 48118
Chelsea, Michigan 48118
Principal Investigator: Samir Narayan
Phone: 734-712-3671
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
Chicago, Illinois 60612
(312) 942-5000
Principal Investigator: Dian Wang
Phone: 312-942-5498
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
Click here to add this to my saved trials
1200 West Harrison Stree
Chicago, Illinois 60607
Chicago, Illinois 60607
(312) 996-4350
Principal Investigator: David J. Peace
Phone: 312-355-3046
Univ of Illinois A major research university in the heart of one of the world's...
Click here to add this to my saved trials
Cincinnati, Ohio 45236
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
Cincinnati, Ohio 45219
Principal Investigator: Jordan Kharofa
Phone: 513-558-4553
Click here to add this to my saved trials
12495 University Ave
Clive, Iowa 50325
Clive, Iowa 50325
(515) 358-9700
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Mercy Cancer Center - West Lakes When it comes to cancer care, there
Click here to add this to my saved trials
Clive, Iowa 50325
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
1400 East Boulder Street
Colorado Springs, Colorado 80909
Colorado Springs, Colorado 80909
Principal Investigator: Brandon D. Bernard
Phone: 719-365-2406
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Dayssy A. Diaz Pardo
Phone: 800-293-5066
Click here to add this to my saved trials
4050 Coon Rapids Blvd NW
Coon Rapids, Minnesota 55433
Coon Rapids, Minnesota 55433
(763) 236-6000
Principal Investigator: Paul W. Sperduto
Phone: 952-993-1517
Mercy Hospital Mercy Hospital, located in Coon Rapids, Minnesota, is a 271-bed non-profit hospital that...
Click here to add this to my saved trials
Cooperstown, New York 13326
Principal Investigator: Timothy P. Korytko
Phone: 607-547-3073
Click here to add this to my saved trials
Creston, Iowa 50801
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
10 Barnes West Drive
Creve Coeur, Missouri 63141
Creve Coeur, Missouri 63141
Principal Investigator: Hiram A. Gay
Phone: 800-600-3606
Click here to add this to my saved trials
1 Wyoming St,
Dayton, Ohio 45409
Dayton, Ohio 45409
(937) 208-8000
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Miami Valley Hospital Miami Valley Hospital (MVH) is passionate about providing the most recent medical...
Click here to add this to my saved trials
2222 Philadelphia Dr
Dayton, Ohio 45406
Dayton, Ohio 45406
(937) 734-2612
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Good Samaritan Hospital - Dayton Good Samaritan Hospital (GSH) is passionate about providing the most...
Click here to add this to my saved trials
Dayton, Ohio 45415
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
Dayton, Ohio 45415
Principal Investigator: Howard M. Gross
Phone: 937-832-1093
Click here to add this to my saved trials
2300 N Edward St
Decatur, Illinois 62526
Decatur, Illinois 62526
(217) 876-8121
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Decatur Memorial Hospital An American flag bearing only 48 stars waved above Decatur Memorial Hospital...
Click here to add this to my saved trials
1111 6th Ave
Des Moines, Iowa 50314
Des Moines, Iowa 50314
(515) 247-3121
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Mercy Medical Center - Des Moines Mercy Medical Center
Click here to add this to my saved trials
Des Moines, Iowa 50314
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
East Lansing, Michigan 48824
Principal Investigator: Jatin Rana
Phone: 517-975-9547
Click here to add this to my saved trials
6401 France Ave S
Edina, Minnesota 55435
Edina, Minnesota 55435
(952) 924-5000
Principal Investigator: Paul W. Sperduto
Phone: 952-993-1517
Fairview Southdale Hospital Fairview Health Services is an award-winning nonprofit health care system based in...
Click here to add this to my saved trials
Effingham, Illinois 62401
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Click here to add this to my saved trials
1900 S Main St
Findlay, Ohio 45840
Findlay, Ohio 45840
(419) 423-4500
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Blanchard Valley Hospital For more than 100 years, Blanchard Valley Hospital has made quality care...
Click here to add this to my saved trials
Findlay, Ohio 45840
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
Click here to add this to my saved trials
1024 S Lemay Ave
Fort Collins, Colorado 80524
Fort Collins, Colorado 80524
(970) 495-7000
Principal Investigator: Brandon D. Bernard
Phone: 970-297-6150
Poudre Valley Hospital A 270-bed regional medical center offering a wide array of treatments, surgeries,...
Click here to add this to my saved trials
Fort Collins, Colorado 80528
Principal Investigator: Brandon D. Bernard
Phone: 412-339-5294
Click here to add this to my saved trials
2200 Randallia Drive
Fort Wayne, Indiana 46805
Fort Wayne, Indiana 46805
Principal Investigator: Brian K. Chang
Phone: 260-373-8888
Click here to add this to my saved trials
Fort Wayne, Indiana 46845
Principal Investigator: Brian K. Chang
Phone: 877-784-4673
Click here to add this to my saved trials
One Medical Center Drive
Franklin, Ohio 45005
Franklin, Ohio 45005
(513) 424-2111
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Atrium Medical Center - Middletown Regional Hospital Atrium Medical Center (Atrium) is built on the...
Click here to add this to my saved trials
Franklin, Ohio 45005
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
550 Osborne Rd NE
Fridley, Minnesota 55432
Fridley, Minnesota 55432
(763) 236-5000
Principal Investigator: Paul W. Sperduto
Phone: 952-993-1517
Unity Hospital Unity Hospital is one of the Twin Cities
Click here to add this to my saved trials
Gilbert, Arizona 85297
Principal Investigator: Jason M. Samuelian
Phone: 480-922-4600
Click here to add this to my saved trials
Glenwood Springs, Colorado 81601
Principal Investigator: Peter J. Rossi
Phone: 970-384-7570
Click here to add this to my saved trials
Goshen, Indiana 46526
Principal Investigator: James A. Wheeler
Phone: 574-364-2973
Click here to add this to my saved trials
Grafton, Wisconsin 53024
Principal Investigator: Ellen L. Ziaja
Phone: 414-302-2304
Click here to add this to my saved trials
Grand Rapids, Michigan 49503
Principal Investigator: Kathleen J. Yost
Phone: 412-339-5294
Click here to add this to my saved trials
100 Michigan St NE
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
(616) 391-1774
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Spectrum Health at Butterworth Campus Butterworth Hospital is one of four facilities that make up...
Click here to add this to my saved trials
1117 29th St S
Great Falls, Montana 59405
Great Falls, Montana 59405
(406) 771-7300
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Benefis Healthcare- Sletten Cancer Institute Benefis Hospitals has 516 beds at its two campuses (that...
Click here to add this to my saved trials
1900 16th Street
Greeley, Colorado 80631
Greeley, Colorado 80631
Principal Investigator: Brandon D. Bernard
Phone: 412-339-5294
Click here to add this to my saved trials
2845 Greenbrier Rd
Green Bay, Wisconsin 54311
Green Bay, Wisconsin 54311
(920) 288-8000
Principal Investigator: Ellen L. Ziaja
Phone: 414-302-2304
Aurora BayCare Medical Center Aurora BayCare Medical Center is a 167-bed, full-service hospital serving the...
Click here to add this to my saved trials
Greenbrae, California 94904
Principal Investigator: Lloyd T. Miyawaki
Phone: 415-925-7325
Click here to add this to my saved trials
835 Sweitzer St
Greenville, Ohio 45331
Greenville, Ohio 45331
(937) 548-1141
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Wayne Hospital Stretching back to our roots nearly 100 years ago, Wayne HealthCare has always...
Click here to add this to my saved trials
Greenville, Ohio 45331
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
Greenville, South Carolina 29605
Principal Investigator: Michael D. Zurenko
Phone: 864-241-6251
Click here to add this to my saved trials
Greenville, South Carolina 29615
Principal Investigator: Michael D. Zurenko
Phone: 864-241-6251
Click here to add this to my saved trials
Greenwood, South Carolina 29646
Principal Investigator: David T. Marshall
Phone: 864-725-4771
Click here to add this to my saved trials
Greer, South Carolina 29650
Principal Investigator: Michael D. Zurenko
Phone: 864-241-6251
Click here to add this to my saved trials
Henderson, Nevada 89052
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Henderson, Nevada 89074
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Henderson, Nevada 89074
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Henderson, Nevada 89052
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
2460 West Horizon Ridge Parkway
Henderson, Nevada 89052
Henderson, Nevada 89052
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Henderson, Nevada 89052
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Jefferson City, Missouri 65109
Principal Investigator: Bryan A. Faller
Phone: 573-632-4814
Click here to add this to my saved trials
Kansas City, Kansas 66160
Principal Investigator: Xinglei Shen
Phone: 913-945-7552
Click here to add this to my saved trials
Kansas City, Missouri 64154
Principal Investigator: Xinglei Shen
Phone: 913-945-7552
Click here to add this to my saved trials
Kenosha, Wisconsin 53142
Principal Investigator: Ellen L. Ziaja
Phone: 414-302-2304
Click here to add this to my saved trials
Kettering, Ohio 45409
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
3535 Southern Blvd
Kettering, Ohio 45429
Kettering, Ohio 45429
(937) 298-4331
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Kettering Medical Center Our flagship hospital, Kettering Medical Center, stands proudly in Kettering, Ohio. From...
Click here to add this to my saved trials
Kettering, Ohio 45420
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
1215 E Michigan Ave
Lansing, Michigan 48912
Lansing, Michigan 48912
(517) 364-1000
Principal Investigator: Samir Narayan
Phone: 734-712-3671
Sparrow Hospital Sparrow has grown to become the region's largest health system, and its diverse...
Click here to add this to my saved trials
Las Vegas, Nevada 89144
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Las Vegas, Nevada 89169
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
9280 W. Sunset Road
Suite 100
Las Vegas, Nevada 89148
Las Vegas, Nevada 89148
702.952.1251
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Comprehensive Cancer Centers of Nevada Comprehensive Cancer Centers of Nevada (CCCN) is the award-winning multidisciplinary...
Click here to add this to my saved trials
Las Vegas, Nevada 89182
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials